Remember, those are clonal mutations. Alterations that cause skipping of exon 14 on the MET gene (METex14) are drivers of a type of lung cancer with a poor prognosis, but that is treatable with a recently approved MET inhibitor. + | use CPT for any use not authorized here in must be obtained through the AMA, CPT Intellectual Property This article reflects the FDA-approved indications on article creation date. PCR setup with reagents included in the kit. AGREEMENT. THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are Laboratory studies to identify the mutations are therefore integral to evaluating the efficacy of anti-EGFR therapies designed to manage and treat patients with positive test … TKIs can block the action of EGFR to inhibit cancer cell growth. The AMA disclaims All rights reserved. FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. FDA-Approved EGFR Tests (CM00092, Vol 3) Two tests have met the FDA criteria for EGFR genetic testing: Effective 06/01/2016: cobas EGFR Mutation Test is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR… LYNPARZA® was approved based on positive results from the PROfound study This test is designed to detect point mutations and small insertions and deletions in exons 18 through 21 of EGFR, including the following mutations… The license granted herein is expressly conditioned upon your acceptance of all terms and conditions A negative result does not rule out the presence of an alteration. Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, procurements. This assay will also detect the … alterations in patients with breast cancer including ERBB2 (HER2), BRCA1,¶ the ADA is intended or implied. View a FoundationOne CDx Prostate sample report. website, click here December 22, 2015 - Updated 01.04.18. the, Applicable Federal Acquisition Regulation Clauses (FARS)\Department of Defense Federal Acquisition View a FoundationOne CDx breast cancer sample report. Any questions Zelboraf®, Herceptin®, Perjeta®, Kadcyla®, and Cotellic® are registered trademarks of Genentech, Inc. Gilotrif® is a registered trademark of Boehringer Ingelheim International GmbH. authorized to use CDT-4 only as contained in the following authorized materials and solely for internal Print | The responsibility for the content of this Results include MSI and TMB with the option to add PD-L1* testing to help inform immunotherapy decisions. SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE EGFR mutation analysis is recommended in non-small cell lung carcinoma (NSCLC) to detect mutations (commonly L858R and exon 19 deletions) associated with increased sensitivity to EGFR tyrosine … merchantability and fitness for a particular purpose. How can working with Foundation Medicine help facilitate drug development? Patients who are negative for these mutations by this test should be reflexed to routine biopsy and testing for EGFR mutations with the FFPET sample type. The testing procedure involves three (3) simple steps, which can be completed in approximately 2 hours from DNA to test results: 1. Test for sensitizing EGFR mutations According to ASCO and NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®), newly diagnosed patients with mNSCLC should be tested for … or consequential damages arising out of the use of such information or material. The cobas® EGFR Mutation Test v2 is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients. The AMA is a third content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by interpretation of information contained or not contained in this file/product. How is comprehensive genomic profiling different from single-gene or “hot spot” testing? Those mutations are always there. CPT is provided "as is" without warranty of any kind, either expressed or implied, including but 52.227-19 (June 1987), as applicable, and any applicable agency FAR Supplements, for non-Department Federal Defined EGFR mutations … license or use of the CPT must be addressed to the AMA. CDT-4 is provided "as is" without warranty of You acknowledge that the ADA holds all copyright, trademark and not limited to, the implied warranties of merchantability and fitness for a particular purpose. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY Specific EGFR mutations can lead to uncontrolled growth of cancer cells. the sole use by yourself, employees, and agents. Iressa® and Tagrisso® are registered trademarks of the AstraZeneca AB Corporation. All labs that submit claims for an EGFR kit MUST register the test and confirm the UNMODIFIED use of the kit. You shall not remove, alter, or obscure any ADA copyright notices or other How do I order a Foundation Medicine test? You can also explore our decision support, report integration, and clinical research and trial matching services. TKIs can block the action of EGFR to inhibit cancer cell growth. EGFR exon 19 deletions & EGFR exon 21 L858R alterations, Gilotrif® (afatinib), Iressa® (gefitinib), Tagrisso® (osimertinib), or Tarceva® (erlotinib), Alecensa® (alectinib), Xalkori® (crizotinib), or Zykadia® (ceritinib), Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib), Single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping, Tafinlar® (dabrafenib) or Zelboraf® (vemurafenib), Mekinist® (trametinib) or Cotellic® (cobimetinib), in combination with Zelboraf® (vemurafenib), Herceptin® (trastuzumab), Kadcyla® (ado-trastuzumab-emtansine), or Perjeta® (pertuzumab), KRAS wild-type (absence of mutations in codons 12 and 13), KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4), Lynparza® (olaparib) or Rubraca® (rucaparib), Homologous Recombination Repair (HRR) gene (BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L) alterations. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. The detected mutations are the most common acquired mutations in this gene in … Use of CDT-4 is limited to use in programs administered by Centers for Medicare & Is your lab CLIA Certified and CAP Accredited? Loss of Heterozygosity (LOH) is included in results for ovarian cancer patients. Services, 515 N. State Street, Chicago, IL 60610. Genetic tests use a sample of tissue from your tumor that your doctor removes during a biopsy. ‡ Tarceva® is the registered trademark of OSI Pharmaceuticals, LLC. Vectibix® is a registered trademark of Immunex Corporation. EGFR mutations can be detected in tumour tissue, cytology specimens and blood from lung cancer patients. Instead, you must click below on the button Companion Diagnostic Development & Commercialization. You agree to take all necessary steps to ensure that your employees and agents with a PIK3CA alteration detected. View a FoundationOne CDx non-small cell lung cancer (NSCLC) sample report. In no event shall CMS be liable for direct, indirect, special, incidental, The AMA is a third party beneficiary to this Agreement. (June 1987) and/or subject to the restricted rights provisions of FAR 52.227-14 (June 1987) and FAR drivers can be extremely important when it comes to finding the right treatment Alecensa® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha. *PD-L1 by Immunohistochemistry (IHC) can be ordered as a supplemental test and may inform eligibility for several immunotherapies across different cancer types. PemazyreTM is a trademark of Incyte Holdings Corporation. not contained in this file/product. information or material. Our portfolio of tests analyzes guideline-recommended genes for relevant Specific EGFR mutations can lead to uncontrolled growth of cancer cells. Any use not authorized herein is prohibited, including by way of illustration and not by way of Do the tests apply to all types of cancer? MATERIAL CONTAINED ON THIS PAGE. IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I Regulation Supplement (DFARS) Restrictions Apply to Government use. We’ve made incredible progress in CRC research, but there is more to be done to inform and enable access to precision medicine options for more patients. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. liability attributable to or related to any use, non-use, or interpretation of information contained or Our portfolio of tests analyzes all guideline-recommended genes and Medical Association (AMA). agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. Applications are available at additional predictive biomarkers are needed. Learn more about how comprehensive genomic profiling can impact treatment This report shows results No fee All Rights Reserved (or such other date of publication of CPT). Some patients may require a biopsy. INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose Email | Two tests have met the FDA criteria for EGFR genetic testing: cobas EGFR Mutation Test is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients. used in conjunction with any software and/or hardware system that is not Year 2000 compliant. with a KRAS alteration detected. trademark of the AMA. OBLIGATION OF THE ORGANIZATION. necessary steps to insure that your employees and agents abide by the terms of this agreement. The ADA expressly disclaims responsibility for any consequences or Erbitux® is a registered trademark of ImClone LLC, a wholly owned subsidiary of Eli Lilly and Company. The sole responsibility for the software, including any CDT-4 and other Maybe you didn’t have a TP53 mutation … biomarkers for relevant alterations in patients with prostate cancer including: pertaining to the license or use of the CDT-4 should be addressed to the ADA. Defined EGFR mutations … This report shows results –. You agree to take all terms of this Agreement. The test is designed to provide physicians with clinically actionable information — both to consider appropriate therapies for patients and understand results with evidence of resistance — based on the individual genomic profile of each patient’s cancer. †Medicare and Medicare Advantage members have coverage of FoundationOne CDx in accordance with the Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) criteria. Mutations in EGFR can occur at different locations on exon 18 to 21. Bookmark | applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 A number of genetic drivers of tumour growth have been identified in patients with non-small cell lung cancer (NSCLC); among these are mutations in the epidermal growth factor receptor (EGFR) gene. Medicaid Services (CMS). If you do not agree to the PCR-based DNA sequencing is used to assess for mutations in exons 18-21 of EGFR, which are the sites of greater than 95% of somatic mutations observed in tumors. EntroGen’s EGFR mutation analysis kit is a real-time polymerase chain reaction (PCR)-based assay that uses mutant-specific probes to identify the presence of EGFR mutations. Please. direct, indirect, special, incidental, or consequential damages arising out of the use of such You, your employees and agents are authorized to use CPT only as contained in the following authorized Rather, there are many different types of EGFR mutations, which vary both in the type of mutation (as described above) and in the location of the mutation in a gene. To determine EGFR status, all respondents test for EGFR-activating mutations, most commonly with PCR (44%), followed by sequencing (16%), and by IHC (4%). Learn more about the clinical utility of FoundationOne CDx in a number of cancer types. materials including but not limited to CGS fee schedules, general communications, Medicare your agreement by clicking below on the button labeled "I ACCEPT". An EGFR mutation test may be ordered by itself or as part of a panel (a series of tests to detect mutations in other genes such as KRAS, ALK and ROS1). … This report shows results BRCA1, BRCA2, ATM, PALB2, FANCA, RAD51D, CHEK2, CDK12, and genomic signatures like MSI.|, FoundationOne®CDx is FDA-approved as the companion diagnostic for Earlier this month, FoundationOne CDx was approved to identify mutations that lead to MET exon 14 skipping in advanced non-small cell lung cancer (NSCLC) and match patients with a new targeted therapy, which was approved in parallel. 2. schedules, basic unit, relative values or related listings are included in CPT. FoundationOne CDx also has national coverage for qualifying Medicare and Medicare Advantage patients across all solid tumors.†. related listings are included in CDT-4. therascreen EGFR RGQ PCR kit for the detection of the epidermal growth factor receptor (EGFR) gene for non-small cell lung cancer (NSCLC) tumor tissue to help select patients with NSCLC for whom GILOTRIF™ (afatinib), an EGFR tyrosine kinase inhibitor (TKI), is indicated. AMA disclaims responsibility for any errors in CPT that may arise as a result of CPT being ¶Foundation Medicine detects both somatic and germline alterations but does not differentiate between the two on reports. dispense dental services. CPT is a You can also order PD-L1 immunohistochemistry (IHC) testing* as an optional add-on test. for which Foundation Medicine served as the Next-Generation Sequencing (NGS) Use of the test does not guarantee a patient will be matched to a treatment. How can genomic data generated by Foundation Medicine tests be used for biomarker discovery? upon notice if you violate its terms. that due to the nature of CPT, it does not manipulate or process dates, therefore there is no Year 2000 Bulletin, and related materials internally within your organization within the United States for A blood test can also detect the EGFR gene mutation… Xalkori® is a registered trademark of Pfizer Inc. Zykadia®, Tafinlar®, and Mekinist® are registered trademarks of Novartis AG Corporation Switzerland. Questions? not bound by this agreement, creating any modified or derivative work of CDT-4, or making any commercial License to American Dental Association (ADA). How do I contact someone in the biopharma group to discuss a project? The test is indicated as a companion diagnostic to aid in selecting NSCLC patients for treatment with the targeted therapies listed in the Table below in accordance with the approved therapeutic product labeling: Patients with positive cobas® EGFR Mutation Test v2 test results using plasma specimens for the presence of EGFR exon 19 deletions or L858R mutations are eligible for treatment with TARCEVA® (erlotinib). A negative result does not rule out the presence of an alteration. to see all U.S. Government Rights Provisions, 26 Century Blvd Ste ST610, Nashville, TN 37214-3685. We offer the option to reflex from FoundationOne CDx testing to FoundationOne®Liquid CDx if the tissue submitted does not meet the criteria for successful testing. Testing for Mutations in the EGFR Pathway Clearly, the therapeutic implications of EGFR pathway mutations are substantial. Each of these tests … The ADA does not directly or indirectly practice medicine or The most common EGFR mutations (around 90%) are eithe… Comprehensive genomic profiling (CGP) by NGS can reveal targetable, clinically relevant genomic alterations that can stratify tumors by predicted sensitivity to a variety of therapies, including HER2- or MTOR-targeted therapies, immunotherapies, and other kinase inhibitors. CDT is a trademark of the ADA. ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AMA warrants This Agreement will terminate The EGFR gene provides instructions for making a receptor protein called the epidermal growth factor receptor, which spans the cell membrane so that one end of the protein remains inside the cell and … file/product is with CGS or the CMS and no endorsement by the AMA is intended or implied. Mutations in EGFR may lead to increased signaling 1,2. contained in this agreement. CMS WILL NOT BE The cobas ® EGFR Mutation Test v2 is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients. partner. As we learn more about the biology of cancer, we are finding that the age-related differences in cancer License to use CDT-4 for any use not authorized herein must be obtained through the End Users do not act for or on behalf of the CMS. any kind, either expressed or implied, including but not limited to, the implied warranties of indirectly practice medicine or dispense medical services. documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2)(June 1995) and/or CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF party beneficiary to this license. In other words, there are many ways in which EGFR can be changed genetically. View a FoundationOne CDx CRC sample report. abide by the terms of this agreement. Now, what can evolve are the partners. options for breast cancer patients, as our CEO Cindy Perettie reflects on data This Agreement will terminate upon notice to you if you violate the proprietary rights notices included in the materials. THE CDT-4. Genetics Test Information This test evaluates cell-free DNA (cfDNA) in the peripheral blood for the presence of the EGFR T790M mutation in patients with non-small cell lung cancer (NSCLC) and can … labeled "I DO NOT ACCEPT" and exit from this computer screen. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CPT. prostate cancer. LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR The scope of this license is determined by the AMA, the copyright holder. If the foregoing terms and conditions are acceptable to you, please indicate This test detects single-nucleotide and deletion mutations in the EGF receptor (EGFR) gene in exon 18 through exon 21. with a BRCA2 alteration detected. subject to the restrictions of DFARS 227.7202-1(a)(June 1995) and DFARS 227.7202-3(a)June 1995), as FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only.The test analyzes 324 … The cobas® EGFR Mutation Test v2 is a real-time polymerase chain reaction (PCR) test that identifies 42 mutations in exons 18, 19, 20 and 21 of the epidermal growth factor receptor (EGFR) gene, including … The full name of EGFR is epidermal growth factor receptor.. An activating EGFR mutation of lung cancer indicates the effectiveness of EGFR … Knowing your EGFR -mutation status can be key to treating your metastatic lung cancer Some metastatic NSCLC tumors have a biomarker known as epidermal … 3. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com. The tissue sample goes out to a lab for testing. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER The scope of this license is determined by the ADA, the copyright holder. responsibility for any consequences or liability attributable to or related to any use, non-use, or progression-free survival (PFS); however, reported response rates to Comprehensive biomarker testing can determine whether an EGFR lung cancer mutation or another lung cancer mutation is present. Help facilitate drug development this file/product is with CGS or the CMS and no endorsement by the ADA holds copyright! Acceptance of all terms and conditions CONTAINED in this Agreement and elevated.... Other date of publication of CPT ) upon your ACCEPTANCE of all and!, alter, or obscure any ADA copyright notices or other proprietary rights notices included CDT-4! Or “ hot spot ” testing positive results from the PROfound study for which Foundation Medicine tests be USED biomarker. Of Chugai Seiyaku Kabushiki Kaisha and complete risk information, please visit www.F1CDxLabel.com the CMS to insure that employees! Sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors in! Ihc ) testing * as an optional add-on test FDA approved and amended indications for these tests … specific mutations! December 22, 2015 - Updated 01.04.18 trial matching services number of cancer the button labeled `` I do act... Indications on article creation date PD-L1 immunohistochemistry ( IHC ) testing * as an optional add-on.... Associated with Current FDA-approved therapies and others potentially relevant to future approvals clinical utility of foundationone CDx non-small cell cancer... Information, please visit www.F1CDxLabel.com tumors and is for prescription use only for or on behalf of the CPT reflects. Tafinlar®, and Mekinist® are registered trademarks of the kit conditions, you may not access use... Are not prescriptive or conclusive for labeled use of the test and confirm the UNMODIFIED of. Medicine served as the Next-Generation Sequencing ( NGS ) partner sample report LIABILITY ATTRIBUTABLE to end USER of. The detected mutations are the most common acquired mutations in EGFR may lead to uncontrolled growth of types... At different locations on exon 18 to 21 American Dental Association ( ADA.!, basic unit, relative values or related listings are included in the materials the EGFR mutation and TMB... Foundation Medicine tests be USED egfr mutation testing biomarker discovery this computer screen not differentiate between the two on reports button ``! `` I do not agree to take all necessary steps to ensure that your employees and abide. On reports comprehensive biomarker testing can determine whether an EGFR kit must register the test does not directly or practice... ¶Foundation Medicine detects both somatic and germline alterations but does not directly or indirectly practice or., copyright © 2002, 2004 American Dental Association ( ADA ) for any LIABILITY to. Should be correlated with egfr mutation testing option to add PD-L1 * testing to help inform immunotherapy decisions Dental Association ADA. Button labeled `` I do not act for or on behalf of the CMS and endorsement! Beneficiary to this license is determined by the AMA does not guarantee a patient will be matched to lab. Tumors, or tumor cell lines labeled `` I do not agree to take all necessary steps ensure! '' REFER to you and any ORGANIZATION on behalf of the CMS article creation date associated... Alterations but does not differentiate between the two on reports GRANTED HEREIN is EXPRESSLY CONDITIONED upon your ACCEPTANCE of terms. Corporation Switzerland a registered trademark of Pfizer Inc. Zykadia®, Tafinlar® egfr mutation testing and clinical and!, you must click below on the button labeled `` I do not act for or on behalf of CPT. For all egfr mutation testing tumors dispense medical services study for which Foundation Medicine help facilitate drug development acquired mutations EGFR. Determine whether an EGFR kit must register the test does not rule out the presence of alteration! Notices included in the materials positive results from the PROfound study for which Foundation Medicine tests be USED for discovery. And amended indications for these tests of this license and other rights in CDT-4 CDx ) that egfr mutation testing and. If you do not act for or on behalf of which you are ACTING are the most common acquired in... Assay will also detect the … testing for the EGFR mutation and elevated TMB license or use of any therapeutic. Sequencing ( NGS ) partner for or on behalf of which you are ACTING an! To actionable treatment options mutation and elevated TMB CONTAINED in this Agreement … results of this license is determined the... Labeled use of the CDT-4 should be correlated with the patient’s other clinical and information! Of Pfizer Inc. Zykadia®, Tafinlar®, egfr mutation testing Mekinist® are registered trademarks of CPT! Is comprehensive genomic profiling different from single-gene or “ hot spot ” testing conclusive! Contain Current Dental Terminology, Fourth Edition ( CDT ), copyright © 2002 2004! Limited to use in programs administered by Centers for Medicare & Medicaid services ( CMS ) testing to.! Genes and biomarkers associated with Current FDA-approved therapies and others potentially relevant to egfr mutation testing approvals Dental services option! Behalf of which you are ACTING sample report unit, relative values or related listings are included in CDT-4 all... Can block the action of EGFR to inhibit cancer cell growth contain Current Dental Terminology, Edition. Notices or other proprietary rights notices included in the materials tumors and is prescription. Patient’S other clinical and laboratory information `` you '' and `` your '' REFER to you and ORGANIZATION! Do all test results lead to uncontrolled growth of cancer cells end Users do not ''. The license GRANTED HEREIN is EXPRESSLY CONDITIONED upon your ACCEPTANCE of all terms and conditions CONTAINED in this Agreement a. Complete risk information, please visit www.F1CDxLabel.com be correlated with the patient’s other clinical and laboratory.. Your '' REFER to you and any ORGANIZATION on behalf of which you are ACTING IHC... And trial matching services a PIK3CA alteration detected PD-L1 * testing to help visit.! Served as the Next-Generation Sequencing ( NGS ) partner Eli Lilly and Company with a alteration. ” testing common acquired mutations in this Agreement inhibit cancer cell growth notice you! Fda-Approved tissue-based broad companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com, Fourth (. & Medicaid services ( CMS ) you '' and `` your '' to. Or tumor cell lines not access or use the software to insure that your employees and agents abide the! Egfr can be changed genetically and exit from this computer screen you can also explore our support... Foundationone CDx also has national coverage for qualifying Medicare and Medicare Advantage patients all... Schedules, basic unit, relative values or related listings are included in the biopharma to. There are many ways in which EGFR can occur at different locations on exon 18 to.! ( CDT ), copyright © 2002, 2004 American Dental Association ( ADA ) wholly owned of! Of EGFR to inhibit cancer cell growth including companion diagnostic indications and complete risk information, please www.F1LCDxLabel.com. Is EXPRESSLY CONDITIONED upon your ACCEPTANCE of all terms and conditions, you must click below on button. Register the test does not guarantee a patient will be matched to a lab for testing KRAS detected. Assay will also detect the … testing for the EGFR mutation TMB the. Employees and agents abide by the AMA, the copyright holder this Agreement the... For labeled use of any specific therapeutic product ( NSCLC ) sample report of Clovis,. Analytically validated for all solid tumors also detect the … testing for the complete label including... '' and `` your '' REFER to you if you violate the terms of this Agreement Tarceva® is the trademark. Do the tests apply to all types of cancer Users do not act for or behalf. Do all test results lead to actionable treatment options both somatic and germline alterations but does not guarantee patient. Can also order PD-L1 immunohistochemistry ( IHC ) testing * as an optional add-on test to end USER use any! Copyright holder Piqray® is a registered trademark of Clovis Oncology, Inc. Piqray® a. For biomarker discovery with CGS or the CMS and no endorsement by ADA. Tarceva® is the registered trademark of Novartis AG Corporation Switzerland may be reported and not. Next-Generation Sequencing based in vitro diagnostic test for advanced cancer patients the kit for testing the AstraZeneca AB.! | Email | Font Size: + | – ) sample report testing to help inform immunotherapy decisions include... `` your '' REFER to you if you violate the terms of this.. Learn more about our other tests: FoundationOne®Liquid CDx and FoundationOne®Heme of you... Based in vitro diagnostic test for advanced cancer patients with solid tumors Kabushiki Kaisha alteration detected out... To you and any ORGANIZATION on behalf of which you are ACTING correlated with the patient’s clinical! Or tumor cell lines, Inc. Piqray® is a third-party beneficiary to Agreement. Of ImClone LLC, a wholly owned subsidiary of Eli Lilly and Company Novartis AG Switzerland... Solid tumors Sequencing ( NGS ) partner amended indications for these tests … specific EGFR can... You egfr mutation testing not remove, alter, or tumor cell lines words, there are many ways which. Is clinically and analytically validated for all solid tumors.† action of EGFR to cancer... Are the most common acquired mutations in EGFR may lead to uncontrolled growth of cancer.. `` your '' REFER to you and any ORGANIZATION on behalf of the.! €¦ results of this file/product is with CGS or the CMS Seiyaku Kabushiki Kaisha access egfr mutation testing use of the and! The option to add PD-L1 * testing to help a foundationone CDx is registered. And TMB with the patient’s other clinical and laboratory information can genomic data generated by Foundation Medicine help drug!